Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 6/20 | 0.48 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | CASP1 | P29466 | 2/20 | 0.46 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4035779 | 0.86 | CTSL (0.50) | SIRT2SIRT1CTSLCTSSCTSK | |
| SCHEMBL4035776 | 0.86 | CTSL (0.50) | SIRT2SIRT1CTSLCTSSCTSK | |
| SCHEMBL1290959 | 0.83 | CTSL (0.52) | SIRT2SIRT1CTSLCTSSCTSK | |
| SCHEMBL1290957 | 0.83 | CTSL (0.52) | SIRT2SIRT1CTSLCTSSCTSK | |
| SCHEMBL4035564 | 0.83 | CTSL (0.52) | SIRT2SIRT1CTSLCTSSCTSK | |
| SCHEMBL4035562 | 0.83 | CTSL (0.52) | SIRT2SIRT1CTSLCTSSCTSK | |
| SCHEMBL27616333 | 0.80 | CTSL (0.61) | CTSLCTSSCTSKCASP1 | |
| SCHEMBL6139194 | 0.80 | CTSL (0.61) | CTSLCTSSCTSKCASP1 | |
| SCHEMBL29399827 | 0.79 | CTSL (0.54) | SIRT2SIRT1CTSLCTSSCTSK | |
| SCHEMBL2064385 | 0.78 | CTSL (0.53) | SIRT2SIRT1CTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312260-A1 | DRUG THERAPY FOR CELIAC SPRUE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2009-12-17 | — | — | US | disclosed |
| US-7605150-B2 | Drug therapy for Celiac Sprue | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2009-10-20 | — | — | US | disclosed |
| EP-1507549-A4 | DRUG THERAPY FOR CELIAC SPRUE | UNIV LELAND STANFORD JUNIOR (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20060035838-A1 | Drug therapy for celiac sprue | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2006-02-16 | — | — | US | disclosed |
| EP-1507549-A2 | DRUG THERAPY FOR CELIAC SPRUE | The Board of Trustees of The Leland Stanford Junior University (US) | 2005-02-23 | — | — | EP | disclosed |
| WO-2003096979-A2 | DRUG THERAPY FOR CELIAC SPRUE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035838-A1 | Drug therapy for celiac sprue | SI, TMPRSS15, DNPEP | SIRT2 2408/4885SIRT1 1928/4885CTSL 172/4885 |
| US-20090312260-A1 | DRUG THERAPY FOR CELIAC SPRUE | SI, DNPEP, SPINT2 | SIRT2 3299/4885SIRT1 3286/4885CTSL 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.